About Glycogenin-2
Glycogenin-2 (GYG2) is a protein
from Homo sapiens identified by UniProt accession
O15488, 501 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | Glycogenin-2 |
| UniProt accession | O15488 |
| Gene | GYG2 |
| Organism | Homo sapiens |
| Length | 501 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (38)
Diseases linked to this target (Open Targets).
- disorder of glycogen metabolism · score 0.37
- acute myeloid leukemia · score 0.22
- low grade glioma · score 0.18
- head and neck squamous cell carcinoma · score 0.13
- primary ovarian insufficiency · score 0.12
- Abnormality of neuronal migration · score 0.11
- Barrett's esophagus · score 0.05
- colorectal adenocarcinoma · score 0.04
- esophageal adenocarcinoma · score 0.04
- cancer · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15488-F1 | alphafold | PREDICTED | 70.93 | — |
Amino-acid sequence (501 residues)
MSETEFHHGA QAGLELLRSS NSPTSASQSA GMTVTDQAFV TLATNDIYCQ GALVLGQSLR RHRLTRKLVV LITPQVSSLL RVILSKVFDE VIEVNLIDSA DYIHLAFLKR PELGLTLTKL HCWTLTHYSK CVFLDADTLV LSNVDELFDR GEFSAAPDPG WPDCFNSGVF VFQPSLHTHK LLLQHAMEHG SFDGADQGLL NSFFRNWSTT DIHKHLPFIY NLSSNTMYTY SPAFKQFGSS AKVVHFLGSM KPWNYKYNPQ SGSVLEQGSA SSSQHQAAFL HLWWTVYQNN VLPLYKSVQA GEARASPGHT LCHSDVGGPC ADSASGVGEP CENSTPSAGV PCANSPLGSN QPAQGLPEPT QIVDETLSLP EGRRSEDMIA CPETETPAVI TCDPLSQPSP QPADFTETET ILQPANKVES VSSEETFEPS QELPAEALRD PSLQDALEVD LAVSVSQISI EEKVKELSPE EERRKWEEGR IDYMGKDAFA RIQEKLDRFL Q
Explore Glycogenin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets